Mobile

A double-blind, placebo-contolled study to evaluate the safety and effect of three experimental drugs ABT-450, ABT-267, and ABT-333 with or without a drug called ribavirin in people with hepatitis C v...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-005522-29

A double-blind, placebo-contolled study to evaluate the safety and effect of three experimental drugs ABT-450, ABT-267, and ABT-333 with or without a drug called ribavirin in people with hepatitis C virus (HCV) that have not been treated before. "Experimental" means that they have not been approved by any regulatory agency for sale to the public

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objectives of this study are to compare the safety of the combination of ABT-450/r/ABT-267 and ABT-333 administered with and without RBV for 12 weeks of treatment with ABT-450/r/ABT-267 and ABT-333 administered with and without RBV compared to the historical SVR rate of telaprevir plus pegIFN and RBV therapy in treatment-naive HCV genotype (GT) 1a-infected adults without cirrhosis.

Critère d'inclusion

  • Chronic Hepatitis C Infection

Liens